Sarah Patterson

Pharmacology graduate student @UNC in the Palmer lab studying curative chemotherapy combinations

[David Steensma, MD @DavidSteensma]

I remember a long-ago @FDAOncology meeting with a small company developing an MDS drug. The company was convinced their drug was synergistic with HMAs & kept saying “we’re 2+2=5.” Finally an FDA official said they were perfectly happy for 2+2 to equal 4, if 4 was safe patients.

[OncoDaily @oncodaily]

You don’t need ‘1+1 makes 3’ if you can have ‘5+5 makes 10’ - @ac_palmer
@NatureCancer @SC_Patterson @PlanaDeborah @DrTonyLetai @DavidSteensma
https://t.co/fY0WVj8kfy

#Cancer #FDAOncology #HypomethylatingAgents #HMAs #NatureCancer #OncoDaily #Oncology

[Adam C Palmer @ac_palmer]

New paper:

Most approved drug combinations for advanced cancer (1995-2020) have predictable clinical efficacy, because they have additive effect on Progression-Free Survival times.

In @NatureCancer at https://t.co/Z7xabVpouT

by @HaeunHwangbo @SC_Patterson @PlanaDeborah
1/6

[Vincent Rajkumar @VincentRK]

I hope we are moving away from “maximum tolerated dose” in oncology. #MedTwitter

Of the studies I’ve led, the one I am most proud of is the trial that showed that LOWER dose of steroids led to better survival & lower toxicity. @TheLancetOncol
#Myeloma https://t.co/LCbAAPST9E

[Ashlee N. Ford Versypt @FordVersyptLab]

#SACB2022 has been a great meeting with exciting research and fun people in a beautiful location. It's been a pleasure serving on the organizing committee over the last 3+ years

[Haeun (Hannah) Hwangbo @HaeunHwangbo]

@SarahCooperUNC was phenomenal at #SACB2022 poster session today!!!

[Sarah Patterson @SC_Patterson]

So proud of @HaeunHwangbo for giving a great talk on clinical drug additivity at #SACB2022!

[Bree Aldridge @AldridgeLab]

Thrilled (and flattered) to read this preview by one of my scientific heroes and leader in the field of drug #combinationtherapy @ac_palmer @SarahCooperUNC

[Dr. Amy Pomeroy @AmyEPomeroy]

I am so excited to share our review of drug independence and its role in curative cancer combination therapy just published #OpenAccess in @TrendsCancer. https://t.co/82ym7yZG7Y #MathOnc #CompMed #SysBio @UNC_PHCO @ac_palmer @UNC_SOM @UNC @UNC_Lineberger (1/8)

[Adam C Palmer @ac_palmer]

2 papers out!

1) Across many cancers, the clinical efficacy of combination immunotherapies is predictable from efficacy of their ingredients
https://t.co/WonMZgn6vY

2) Review - what does this mean for precision oncology?
https://t.co/ewU3jdFnWl

1/n

[Sarah Patterson @SC_Patterson]

So proud of our postdoc @AmyEPomeroy for creating a model that can accurately predict clinical trial outcomes!

[Dr. Amy Pomeroy @AmyEPomeroy]

I've developed a model of combination chemotherapy and trained it on DLBCL trials. The ultimate test of my model is to predict new trial results, so I predicted the results of the POLARIX trial. Today I got to check the predictions, and they were right!

https://t.co/wQQYXNDqWh

[Dr. Amy Pomeroy @AmyEPomeroy]

I'm so excited to share the primary article from my graduate work, published today in @scisignal! I am so proud of this project and thankful for all of my coauthors including @matthewipena and @beveunc.

@CompMedUNC @UNC_BCBP @UNC_PHCO @UNC_SOM

https://t.co/IBOG4gVZHT

[Sarah Patterson @SC_Patterson]

Thank you @UNC_TIBBS for hosting an ornament decorating party! Definitely brought some joy during a hard year. #TIBBSholidaze

[Sarah Patterson @SC_Patterson]

Couldn't have said it better myself!

[Dr. Amy Pomeroy @AmyEPomeroy]

Friday meetings with these amazing women to set new goals, celebrate how we crushed last week’s goals, and identify ways we can continue to improve is always the highlight of my week.

Women supporting other women in science is NEVER a bad thing.

[Sarah Patterson @SC_Patterson]

@AmyEPomeroy YES I love this

[Dr. Amy Pomeroy @AmyEPomeroy]

Whenever my husband’s students mistakenly address him as Dr. Pomeroy, he corrects them saying “Dr. Pomeroy is my wife” #WomenInSTEM

[Bill Nye @BillNye]

I got a flu shot. Protects me. Protects you from me. Please get one, too!

[Pharmacoengineering & Mol Pharmaceutics (DPMP UNC) @DPMP_UNC]

Congrats @Aaron_Anselmo on another NIH NOA, this time for a diversity supplement for @UNCBBSP Microbiology and Immunology grad student Jilarie Santos Santiago. Terrific news for such a fantastic student!